See Graham's ranking
4.0
Harmony Biosciences Holdings, Inc. operates within the Health Care sector, under the Biotechnology subsector, and is listed on Nasdaq under the ticker HRMY. Its origins trace back to a group of pharmaceutical industry executives, supported by biotechnology-focused investment funds, with the objective of developing therapies for rare neurological disorders and conditions related to the central nervous system.
The initial motivation involved identifying therapeutic gaps in low-prevalence diseases, directing efforts toward neuroscience research that requires specialized regulatory processes, high clinical precision and the capability to develop innovative molecular treatments.
The product and service portfolio focuses on the development, manufacturing and commercialization of therapies targeting neurological disorders, including treatments for narcolepsy and other conditions affecting the sleep–wake cycle. It also includes clinical programs at various stages, as well as medical monitoring activities, clinical trials and scientific support for healthcare professionals.
The market footprint is predominantly domestic, concentrated in the United States, with gradual expansion into international research partnerships and potential commercial licensing opportunities. Collaboration with academic institutions and clinical centers across several U.S. states broadens the reach of multicenter studies and scientific networks.
Market factors influencing performance include FDA regulatory policies, drug approval cycles, the pace of innovation within biotechnology, research and development costs and competition from companies pursuing treatments for rare diseases and specific neurological disorders.
Organizational size comprises several hundred employees distributed across research, regulatory affairs, commercial operations and clinical development. The patient base includes thousands of individuals diagnosed with neurological disorders, depending on therapeutic eligibility and coverage within healthcare systems.
The operational structure involves contracted research laboratories, clinical support units, partnerships with contract research organizations (CROs) and internal regulatory management functions. Corporate headquarters are located in Plymouth Meeting, Pennsylvania, supported by remote and regional teams responsible for medical, scientific and commercial operations.
The company’s securities are traded under the ticker HRMY, exclusively on Nasdaq.
History and Foundation
Harmony Biosciences was founded in 2017 in the United States, with initial headquarters in Pennsylvania. Its establishment aimed to build a platform dedicated to developing therapies for rare neurological diseases, with a focus on bringing innovative treatment options to market.
During its early years, challenges included structuring clinical studies, building a consistent development pipeline and achieving regulatory alignment with the FDA. Initial milestones included securing licenses for the development of specific molecules and advancing research programs into subsequent clinical phases.
Expansion unfolded through portfolio strengthening, broader clinical trial activity and institutional partnerships with research centers. New therapeutic areas were evaluated, reinforcing the company’s positioning within neuroscience.
Key milestones include the initial launch of its lead treatment in 2019, the execution of its initial public offering (IPO) in 2020 and the advancement of multicenter clinical studies across multiple research phases. The corporate structure underwent adjustments to support commercial and regulatory growth.
From 2020 to 2024, relevant developments included pipeline expansion, clinical-trial updates, contractual adjustments with strategic partners, additional regulatory analyses and changes in stock performance driven by clinical outcomes, revised projections and broader sector dynamics in the biotechnology market.
Additional Information
The Company Harmony Biosciences Holdings Inc. (United States), is listed on Nasdaq with a market cap of $ 1.99 Billion, having an equity of $ 835.12 Millions.
With a total of 150 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.
In the last 12 months the Company had a revenue of $ 825.95 Millions, which generated a profit in the amount of $ 185.69 Millions.
As for its main indicators, the Company has a P/E ratio of 10.72, a P/BV ratio of 2.38 and in the last 12 months the Company did not pay dividends.
The Company is traded internationally through the ticker HRMY.
